Flputnam Investment Management Co. Has $592,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

Flputnam Investment Management Co. lessened its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 17.3% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 3,013 shares of the medical research company’s stock after selling 630 shares during the quarter. Flputnam Investment Management Co.’s holdings in IQVIA were worth $592,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. US Bancorp DE boosted its holdings in shares of IQVIA by 62.2% during the third quarter. US Bancorp DE now owns 27,061 shares of the medical research company’s stock worth $6,413,000 after acquiring an additional 10,379 shares during the period. Farther Finance Advisors LLC boosted its stake in IQVIA by 35.2% in the 3rd quarter. Farther Finance Advisors LLC now owns 407 shares of the medical research company’s stock valued at $96,000 after purchasing an additional 106 shares during the period. Chicago Partners Investment Group LLC acquired a new position in IQVIA in the 3rd quarter valued at $218,000. Optas LLC bought a new position in IQVIA during the 3rd quarter worth $210,000. Finally, Conning Inc. acquired a new stake in shares of IQVIA during the third quarter worth $206,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on IQV shares. Morgan Stanley raised their price target on shares of IQVIA from $245.00 to $250.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Bank of America dropped their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Stifel Nicolaus cut their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating for the company in a research note on Friday, February 7th. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Finally, JPMorgan Chase & Co. cut their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a research report on Tuesday, February 18th. Four research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $251.22.

IQVIA Stock Performance

NYSE IQV opened at $184.67 on Tuesday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a fifty-two week low of $184.06 and a fifty-two week high of $261.73. The stock has a market cap of $32.52 billion, a PE ratio of 24.62, a PEG ratio of 1.99 and a beta of 1.48. The firm’s fifty day moving average price is $198.84 and its two-hundred day moving average price is $214.25.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.